Literature DB >> 2499460

Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction.

T Linden1, G Bondjers, G Camejo, R Bergstrand, L Wilhelmsen, O Wiklund.   

Abstract

In the present study, the hypothesis that the affinity of LDL to arterial proteoglycans might discriminate myocardial infarction patients from controls were tested. The patients were 52 men who had sustained a myocardial infarction at an age of 50 years or less and the controls, selected from a random population sample, were matched to the patients for age and sex. Serum cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol and apoB discriminated patients from controls. In addition, LDL reactivity with arterial proteoglycans was significantly higher in patients than in controls. In a multiple regression analysis, with patient or control as the dependent variable, apoB levels, LDL proteoglycan reactivity and serum triglycerides appeared as independent contributors to the regression. These observations indicate that LDL reactivity with arterial proteoglycans is a new, highly significant factor which discriminates between young myocardial infarction patients and controls.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499460     DOI: 10.1111/j.1365-2362.1989.tb00193.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.

Authors:  J Borén; K Olin; I Lee; A Chait; T N Wight; T L Innerarity
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

Review 2.  The response-to-retention hypothesis of early atherogenesis.

Authors:  K J Williams; I Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

3.  Caloric restriction: powerful protection for the aging heart and vasculature.

Authors:  Edward P Weiss; Luigi Fontana
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-12       Impact factor: 4.733

Review 4.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

5.  Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients.

Authors:  Osman Ahmed; Karin Littmann; Ulf Gustafsson; Camilla Pramfalk; Katariina Öörni; Lilian Larsson; Mirko E Minniti; Staffan Sahlin; German Camejo; Paolo Parini; Mats Eriksson
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

Review 6.  ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker.

Authors:  Eva Hurt-Camejo; Germán Camejo
Journal:  J Cardiovasc Dev Dis       Date:  2018-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.